EU bans 700 generic drugs for manipulation of trials by GVK Biosciences
The European Union has banned the marketing of around 700 generic medicines for alleged manipulation of clinical trials conducted by India's pharmaceutical research company GVK Biosciences.
The largest EU-wide suspension of sales and distribution of generic drugs ordered by the European Commission will come into effect on August 21 and it will be applicable to all 28 member nations, according to Germany's drug regulator, the Federal Institute for Medicines and Medical Products. European commission had taken decision in this regard in response to a recommendation given by the EU’s nodal drug regulator European Medicines Agency (EMA) in January 2015. In its recommendations EMA had mentioned that the marketing authorisations of these drugs were based on clinical trial data which was allegedly manipulated by the Indian company. With this ban, medicines 700 generic medicines will lose their validity for use in the EU from and no longer they will be distributed or sold by pharmaceutical companies, drugs stores wholesale dealers and other outlets.